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Abstract
Background: The transcription factor PAX6 is expressed in various cancers. In anaplastic astrocytic glioma, PAX6
expression is inversely related to tumor grade, resulting in low PAX6 expression in Glioblastoma, the highest-grade
astrocytic glioma. The aim of the present study was to develop a PAX6 knock out cell line as a tool for molecular
studies of the roles PAX6 have in attenuating glioblastoma tumor progression.
Methods: The CRISPR-Cas9 technique was used to knock out PAX6 in U251 N cells. Viral transduction of a doxycycline
inducible EGFP-PAX6 expression vector was used to re-introduce (rescue) PAX6 expression in the PAX6 knock out cells.
The knock out and rescued cells were rigorously characterized by analyzing morphology, proliferation, colony forming
abilities and responses to oxidative stress and chemotherapeutic agents.
Results: The knock out cells had increased proliferation and colony forming abilities compared to wild type cells,
consistent with clinical observations indicating that PAX6 functions as a tumor-suppressor. Cell cycle distribution and
sensitivity to H2O2 induced oxidative stress were further studied, as well as the effect of different chemotherapeutic
agents. For the PAX6 knock out cells, the percentage of cells in G2/M phase increased compared to PAX6 control cells,
indicating that PAX6 keeps U251 N cells in the G1 phase of the cell cycle. Interestingly, PAX6 knock out cells were more
resilient to H2O2 induced oxidative stress than wild type cells. Chemotherapy treatment is known to generate oxidative
stress, hence the effect of several chemotherapeutic agents were tested. We discovered interesting differences in the
sensitivity to chemotherapeutic drugs (Temozolomide, Withaferin A and Sulforaphane) between the PAX6 expressing
and non-expressing cells.
Conclusions: The U251 N PAX6 knock out cell lines generated can be used as a tool to study the molecular functions
and mechanisms of PAX6 as a tumor suppressor with regard to tumor progression and treatment of glioblastoma.
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Background
Malignant gliomas are tumors of glial cell origin. The
most common and aggressive brain tumor in adults is
Glioblastoma (GBM), consisting of cells with astrocytic
features. GBM can arise either as a primary tumor, or
from anaplastic astrocytoma (AA). While AAs are grade
III tumors according to World Health Organization
(WHO) [1], GBM is grade IV, the highest-grade astrocy-
toma [2], defined by uncontrolled proliferation, infiltra-
tion, proneness for necrosis, sturdy angiogenesis and
genomic instability [3]. Surgical cure is nearly impossible
due to early invasion into the central nervous system.
Only 10% of patients getting surgical treatment com-
bined with radiotherapy and chemotherapy survive
5 years after diagnosis [4, 5]. Chemotherapeutic treat-
ment options are few and efficacy poor for glioma pa-
tients. In addition, chemotherapy resistance is common
[6]. Overall, patient survival is approximately 12 months
from diagnosis [7, 8]. For reasons unknown, incidence of
GBM is rising, and there has been very little improve-
ment in clinical outcomes for GBM patients over the last
decade [9]. Increased knowledge about the genetics of
GBM is crucial for developing new, targeted therapy.
PAX6 is a transcription factor involved in embryonic
brain development, and is also present in the adult brain
[10–12]. It has been shown that PAX6 is expressed in a
number of different cancer cell lines, and that it can act
as a tumor suppressor or in an oncogenic manner,
depending on the tissue affected [13–16]. In gliomas,
PAX6 acts as a tumor suppressor reducing tumor
growth [16], and PAX6 expression is reduced with the
malignancy of glioma [17, 18]. PAX6 is used as a
prognostic marker for malignant astrocytic gliomas,
where low levels of PAX6 expression in AA and GBM
correlates with unfavorable patient outcomes [18]. GBM
expresses lower levels of PAX6 compared to adjacent
healthy tissue, and AAs typically have three folds more
PAX6 expression compared to GBM [18]. There has not
been identified PAX6 mutations in gliomas, and the lower
expression is probably caused by epigenetic changes as the
tumors develop [19].
PAX6 is found to suppress cell proliferation, cell
invasiveness, and colony formation. In glioblastoma cell
lines, ectopic PAX6 expression downregulates matrix
metalloproteinase-2 (MMP2) and suppresses invasive-
ness [20]. PAX6 is also involved in inhibiting angiogen-
esis in gliomas, as it is found to downregulate expression
of vascular endothelial growth factor A (VEGFA) [21],
the main angiogenic factor overexpressed in GBM.
PAX6 has been showed to inhibit WNT5A-mediated glio-
blastoma stem cell (GSC) differentiation into endothelial-
like cells, where silencing of PAX6 by activation of the
AKT- pathway increased proliferation, vascularization,
and invasive growth [22]. There are also strong indications
that PAX6 is involved in regulating glioblastoma cell cycle
by arresting cells in G0/G1-phase, leading to slower prolif-
eration [17]. Chang and colleagues showed that U251 glio-
blastoma cells are more sensitive to oxidative stress when
overexpressing PAX6 [3, 23]. The common chemothera-
peutic treatment option Temozolomide (TMZ) has been
shown to increase PAX6 expression, and to depend on
PAX6 to function [24]. However, the mechanisms behind
the tumor suppressor functions of PAX6 in glioblastoma
are not fully revealed, and further studies are needed both
for the development of new drugs, and for the under-
standing of the observed resistance to present glioblast-
oma drug treatments.
In the present study, we have used the CRISPR-Cas9
technology to knock out PAX6 in a commonly used cell
line for GBM research, namely U251. We have investi-
gated the morphologies of our knock out (KO) cells and
have shown that the removal of PAX6 causes increased
proliferation, migration and colony forming abilities.
Furthermore, we have observed a shift in the cell cycle
distribution of the PAX6 KO cells compared to WT
cells. Interestingly, we also found that PAX6 KO cells
are more resilient than WT cells to oxidative stress. This
was confirmed by reintroducing PAX6 into the KO cells
by retroviral transduction.
Methods
Cell culture and treatment
The U251 N cell line was a kind gift from Dr. Hrvoje
Miletic, University of Bergen, Norway [25]. The U251 N
cells, the CRISPR-Cas9 cells generated from U251 N (this
paper), and the HEK Phoenix cells (ATTC #CRL-3213)
were all cultured in Dulbecco’s Modified Eagle’s Medium -
high glucose (cat#D5796 Sigma) supplemented with 10%
FCS (Biochrom AG, Berlin, Germany) and 1% penicillin/
streptomycin (cat#P0781, Sigma). Cells were transfected
using Lipofectamine 2000 (cat#11668–019, Invitrogen,
Calsbad, CA). Authentication of the original U251 N cell
line and generated cells, were performed at the accredited
(ISO/IEC 17025) Centre of Forensic Genetics, University
of Tromsø – The Arctic University of Norway. No ethics
approval and informed consent were required to use any
of the above mentioned cell lines in this study.
Generation of PAX6 KO cell-lines by CRISPR-Cas9 genome
editing
Oligos for guide RNAs were selected with the help of an
online CRISPR-Cas9 Design tool, crispr.mit.edu/. We
chose three of the guide RNA sequences suggested by the
program and added 5’CACCG-3′ to the five prime end of
the oligo. Oligos for guide RNAs are displayed in Table 1.
The guide RNA sequences chosen had the least number
of potential off-target sites calculated by the CRISPR Cas9
Design tool. Annealed guide oligos were cloned into the
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CRISPR-Cas9 expression vector pSpCas9 (BB)-2A-GFP
(PX458) (#48138 Addgene plasmid [26]. The vector was
linearized by BbsI (cat#R0539S New England BioLabs),
and guide oligos were cloned into the vector by T4 DNA
ligase (cat#15224–041, Invitrogen). The three different
plasmids were separately transfected into U251 N cells.
The next day, single cells were sorted into 96-well plates
by FACS. Two weeks later colonies emerged and single
colonies were expanded into 6 well plates. PAX6 knockout
cells and PAX6 control cells were selected by western blot.
Successful knockout was verified by genome sequencing:
The N-terminal part of PAX6 was PCR amplified by use
of the PAX6 oligos (Table 2). The PCR product was by
Zero Blunt PCR cloning kit (Invitrogen cat#44–0302) and
transformed into E.coli DH5-alpha. Colonies were
sequenced by M13 primers. Four PAX6 positive single cell
clones were verified by sequencing and kept as controls.
Potential off-target sites were also sequenced. A list of
potential off-target sites were generated by the online
CRISPR Cas9 Design tool, crispr.mit.edu/. We chose the
two potential off target-sites that were located in an exon
or splice sites. For guide 2, these sites were located in
NOL6 (Nucleolar Protein 6) and PPP1R9A (Protein Phos-
phatase 1 Regulatory Subunit 9A). Primers used for ampli-
fication of the genomic areas are displayed in Table 2, and
cloning and sequencing were done as described above The
cells were used in experiments for a maximum of five
passages after pooling single cells clones, to avoid the
potential of one clone dominating the pool.
Generation of doxycycline inducible EGFP-PAX6 rescue
cells
Retroviral transduction was used to stably reintroduce
PAX6 into knockout cells. PAX6 was cloned into pDest-
LRT-EGFP (gift from Trond Lamark, University of
Tromsø – The Arctic University of Norway) by gateway
cloning (Gateway LR clonase cat#11791–020 BP clonase
cat#11789–020, Invitrogen, Calsbad, CA). The resulting
plasmid pLRT-EGFP-mPAX6, was transfected into HEK
Phoenix cells (ATTC# CRL-3213) producing gag-pol
and envelope protein. Supernatant was harvested and
sterile filtrated at day 2 and 3 after transfection. 2 ml of
25% supernatant in culture medium and 5 mg/ml
proteaminsulfate was added to individual U251 PAX6
KO cell lines. The following day 1 ml supernatant was
removed from cells and 3 ml culture medium was added.
24 h later the cells were washed 2 times in culture
medium. Infected cells were selected by 10 μg/ml
blasticidin (cat#A11113903 GIBCO, Thermo Fischer).
Verification of inducible EGFP-PAX6 was done by
titration of doxocyclin (Dox) (cat#D3447, Sigma) at the
concentrations; 10, 25, 50, 100, 250 and 500 ng/ml and
visualization by green fluorescence and anti-PAX6
western blot. A concentration of 10 ng/ml Dox was used
for experiments if not otherwise indicated in the text.
When indicated, EGFP-PAX6 expressing cells were
FACS sorted 1 day after stimulation with 100 ng/ml
Dox, for use in experiments The cell sorting was done
on a FACSAria III from Becton & Dickinson (BD) at the
Advanced Microscopy Core Facility (AMCF) at the
Faculty of Health Sciences, UiT – The Arctic University
of Tromsø, Norway.
Western blots
Cell lysates were prepared by washing 90% confluent cells
in 6 well plates with PBS, detaching and scraping in 100 μl
2xSDS PAGE buffer (100 mM Tris-HCl, pH 6.8, 4% SDS,
20% glycerol, 0.2% bromphenolblue and freshly added
DTT to 0.2 M). Cells were boiled at 100 °C for 5 min. Cell
lysates were sonicated 2.5 min in a icecold water bath,
using the Bioruptor (Diagenode) with settings “High”, 30 s
on/off cycles. Samples were briefly centrifuged before
being loaded in premade gels (cat# NW04122BOX Invi-
trogen). See Blue Plus2 Prestained Standard (cat#LC5925
Invitrogen), Super Signal Molecular Weight protein ladder
(cat#84785, Thermofisher) and MagicMark XP Western
Protein Standard (cat#LC5602 Invitrogen) were used as
molecular weight markers. Gels were run 35 min, at
200 V, 120 mAmpere. Proteins were blotted onto Li-Cor
Odyssey nitrocellulose membranes (cat #926–31,092).
Rabbit anti-PAX6 antibody (cat#AB2237, Millipore) at 1:
1000 and mouse anti-Pax6 antibody(Cat# pax6, RRID:AB_
528427, Developmental Studies Hybridoma Bank,
University of Iowa) at a 1:37 dilution was used for screen-
ing single cell clones, and rabbit anti-Actin (cat#A2066,
Table 1 Guide RNA sequences
Guide 1 Forward 5’-CACCGTGTCAACGGGCGGCCACTGC-3′
Reverse 5′- AAACGCAGTGGCCGCCCGTTGACAC-3′
Guide 2 Forward 5’-CACCGAGCGGAGTGAATCAGCTCGG-3′
Reverse 5′- AAACCCGAGCTGATTCACTCCGCTC-3’
Guide 3 Forward 5′- CACCGTGGTGTCTTTGTCAACGGG-3’
Reverse 5′- AAACCCCGTTGACAAAGACACCAC-3’
Table 2 Primers for amplification of target- and off-target genomic DNA
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Sigma-Aldrich) at a 1:1000 dilution as a loading control.
Anti-rabbit 680LT (cat#926–68,023), anti-rabbit 800CW
(cat#926–32,213) or anti-mouse 800 CW (cat#926–
32,212) IRDye secondary antibodies (LI-COR Biosciences)
were used at a dilution of 1:10000 in TBST. Images were
acquired on Odyssey Sa (LI-COR Biosciences).
Immunocytochemistry
Cells (50000) were seeded at sterile fibronectin coated
coverslips in 24 well plates, and left in a cell incubator
overnight (ON). The cells were fixed in 4% paraformal-
dehyde, 20 min at room temperature (RT), washed in
1xPBS and permeabilized by Methanol, 5 min, RT. Cells
on coverslips were washed in PBS and blocked using 5%
BSA, 20 min, RT. PAX6 primary antibody was added
(Cat# pax6, RRID:AB_528427, Developmental Studies
Hybridoma Bank, University of Iowa) at a dilution of 1:
37 in PBS, 1% BSA, 1 h, RT. The coverslips were washed
in PBS, 1% BSA containing DAPI, and subsequently
incubated in secondary antibody (Alexa Fluor® 555-
conjugated goat anti-mouse IgG, Cat# A-32727 (1:1000).
Life Technologies and Alexa Fluor® 647-conjugated goat
anti-rabbit IgG (Cat# A32733 (1:5000)). One hour later
the coverslips were washed repeatedly in PBS, 1% BSA
and then in H2O. The coverslips were attached to object
glass using Mowiol mounting media and left to dry ON
at RT. The next day the cells were photographed by
Zeiss LSM 780 inverted confocal microscope with a
63 × 1.4 plan-Apochromat NA objective at different
wavelengths of light to visualize EGFP and secondary
antibody tags.
Colony-forming assay
Cells were seeded in 6 well plates in triplicates of either
200, 500 or 1000 cells/well. The cells were incubated for
12 or 16 days in culture medium. At day 12 or 16, cells
were fixed 5 min in 3:1 methanol: acetic acid and then
stained 15 min in 0.005% crystal violet. Colonies were
counted and the percent of cells forming colonies com-
pared to plated cells (100%) were calculated. Morphology
of clones and cells in general, were investigated by use of
Zeizz Axiovert S100 microscope and the NIS-Elements
Documentation software (Nikon).
Migration assay
Cells were seeded in Ibdi 2 well silicone inserts (Ibdi cat#
81176) in 24 well plates; 20,000 cells per insert well to
obtain 95–100% confluency the next day. To inhibit further
cell proliferation, the cells were treated with 50 μg/ml Mito-
mycin C (cat# M4287, Sigma) in complete culture medium
for 2 h. The cells were washed twice with complete
medium, and inserts were removed. The cell gaps were
photographed (timepoint 0). Cells were returned to the
tissue culture incubator and photographed again after 20,
48 and 72 h, at the same positions along the gap. The
distance of cell migration was calculated by digitally draw-
ing ten evenly spaced horizontal lines from edge to edge of
the wounds at 0 and 20 h using NIS Elements BR 2.3
(Nikon). The mean value was calculated for each scratch.
For each experiment, 4–10 scratches were measured per
cell type. Three independent experiments were analyzed.
To determine the statistical relevance of differences in
migration between the different cell lines, Student’s t-test
was performed.
Proliferation assay
Cells were seeded in 6 well plates, 50,000 cells per well,
done in triplicate at Day 0, and counted on Day 1, 2 and
3 by use of a hematocytometer. Alternatively, 2200 or
4400 cells were seeded per well in 96 well dishes and
analysed by Cell Titer Glo (G7571, Promega) according
to the manufacturers instruction. This assay detect ATP,
and thus the amount of viable cells in a culture. The lu-
minescence was recorded using a CLARIOstar micro-
plate reader (BMG Labtech).
Cell cycle assay
Cells at 70–90% confluency were detached by trypsin and
washed twice in PBS. PBS was removed, leaving 200 μl for
resuspension. While carefully vortexing cells, 2 ml cold
70% EtOH was added dropwise. Cells were incubated at
4 °C for a minimum of 1 h. After washing twice in PBS,
cells were resuspended in 200 μl 50 μg/ml Propidium iod-
ide (cat#P4170 Sigma) diluted in dH2O. 50 μl 100 μg/μl
RNase A (cat#EN0531 Thermo Scientific) was added, and
cells were left in the dark, at room temperature for
30 min, before analyzing by flow cytometry in a LSR
Fortessa (BD).
Oxidative stress and apoptosis assay
Cells were seeded to 50% confluency in complete medium.
The next day medium was replaced with 300 μM hydro-
gen peroxide containing medium, and left for 24 h.
Medium was collected and cells were washed in PBS that
was collected. Cells were trypsin treated, and the previ-
ously collected medium was used to inactivate the trypsin.
Cells, collected medium and PBS were centrifuged at
1200 rpm, 3 min. Cells were further treated according to
protocol of the FITC Annexin VApoptosis Detection Kit I
(cat#556546 BD Pharmigen), and analyzed by flow cytom-
etry at PI and FITC channels in a LSR Fortessa (BD).
Chemotherapy treatment of cells
At 50% confluency, cell growth medium containing che-
motherapeutic agents were added to the cells for a 72 h
incubation. DMSO was used as a solvent. The concentra-
tions were as follows: Temozolomide (TMZ) (cat#T2577,
Sigma Aldrich) 250 μM, Withaferin A (WA) (cat#W4394,
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Sigma Aldrich) 1.5 μM, Sulforaphane (SFN) (cat#574215,
EMD Millipore) 10 μM. Cells were also incubated in
growth medium containing 0.2% DMSO, or in growth
medium. Cells were photographed and apoptosis assays
were performed as described above.
RNA extraction and reverse transcriptase-qPCR
RNA purification, cDNA synthesis and qPCR reactions
are previously described in [27]. Housekeeping genes for
standardizations were TFRC and GAPDH. The primer
pairs for the housekeeping genes and for MMP2 were
purchased as KiCqStart primers from SIGMA (PrimerPair
ID: H_TFRC_1, H_GAPDH_2 and H_MMP2_1). Other
primers were designed by use of Primer3 [28]. Primer3
designed primer pairs for qPCR are shown in Table 3.
Results
Establishing PAX6 knockout cells by CRISPR-Cas9
technology
The CRISPR-Cas9 technology was used to knockout
PAX6 from the U251 N glioblastoma cell-line. Three
different guide RNAs were chosen (crispr.mit.edu/). The
guide RNAs were designed to create mutations close to
the 5’end of the PAX6 gene, between positions + 25 to +
58 relative to the transcription start site (TSS)
(Additional file 1: Figure S1). The PAX6 protein expres-
sion in expanded single cell clones were evaluated by
western blot using anti-PAX6 antibody. One of the guide
RNAs produced several PAX6 knockout (KO) clones. In
addition, some of the single cell clones had a marked
reduction in PAX6 expression compared to wild type
(WT) U251 N cells, indicative of heterozygous knockout
of PAX6 (data not shown). Sequencing of PAX6 KO cells
showed that cell lines originating from single cell clones
had a variety of mutations creating stop codons down-
stream of the TSS (Additional file 2: Figure S2), there-
fore it will not be correct to label them as clones and
they will hereby be referred to as cell lines or simply
cells. We selected three PAX6 KO cell lines obtained by
use of guide 2, namely 2.10, 2A.3 and 2A.28. As control
cells, we used four single cell clones that had been
through the CRISPR-Cas9 protocol of transfection and
selection but remained PAX6 positive, namely 1.7, 1A.9,
1A.26 and 1A.67. By performing western blot (Fig. 1a)
and immunocytochemistry (ICC) (Fig. 1b) using anti-
PAX6 antibody, we verified the absence of PAX6 in the
knockout cells. All the PAX6 KO cell lines were further
transduced with a retroviral vector containing a
Doxycycline (Dox) inducible EGFP-PAX6 gene to create
cells that are PAX6 expression “rescued”. We observed a
concentration dependent induction of PAX6 expression
when Dox concentrations between 10 ng/ml and
500 ng/ml were tested (data not shown). A concentra-
tion of 10 ng/ml Dox was sufficient to induce a PAX6
expression similar to that of WT cells (data not shown),
and this concentration was therefore used for further
experiments with the PAX6 Rescue cells. Figure 1C
shows a western blot of the three different PAX6 Rescue
cell lines with and without Dox. The uninduced cells do
not show EGFP-PAX6 expression (nor PAX6 expres-
sion). However it should be noted that for some experi-
ments we observed weak EGFP-PAX6 expression without
the addition of Dox, indicating leakiness of the inducible
system. Leakiness of inducible expression systems is not an
unusual phenomenon [29, 30]. The presence of PAX6 in
the Rescue cells were confirmed by comparing ICC of the
pooled PAX6 KO cells and pooled PAX6 Rescue cells. In
addition to the green fluorescence mediated by the EGFP-
tagged PAX6 protein, cells were DAPI stained, and
immune-stained by PAX6 antibody (Fig. 1d). The intensity
and location of the green fluorescence and the PAX6
immunostaining coincided and thereby confirmed induced
expression of the EGFP-PAX6 protein. However, it also
showed significant variability in the amount of PAX6
protein expressed in individual cells upon Dox induction.
The variability in PAX6 expression amongst cells cannot be
detected by western blot. Although it should be considered
when performing experiments on the Rescue cells as PAX6
is known to have dose dependent effects.
Morphological variations amongst the PAX6 KO cell lines
It was apparent that there were morphological varieties in
the PAX6 KO cells compared to the U251 N WT cells
(Fig. 2). U251 cells are a mixture of morphological diverse
cells that also form different types of colonies [31]. The
WT cells consists of elongated neuron-like cells and some
shorter cells. The U251 CRISPR-Cas9 PAX6 control 1.7
cells retains morphology as U251 N WT, whereas the
PAX6 KO 2.10 cells have shorter triangular cobblestone-
like morphology (Fig. 2a). The PAX6 KO cell lines 2A.3
and 2A.28 show similar morphology to WT, with 2A.28
having elements of the cobblestone morphology of the 2.
Table 3 qPCR primer pairs
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10 cells (Fig. 2a). However, all three KO cell lines consist
of varieties of cell shapes and sizes that are all present
more or less in U251 N WT. However, each of them have
the dominating cell morphologies described above. The
three KO cell lines (2.10, 2A.3 and 2A.28) were pooled to
diminish potential clonal effects in further experiments.
We also pooled four different CRISPR-Cas9 PAX6 control
cell lines, amongst these the 1.7 cells. Even though the
pooled KO cells consisted of morphological divergent
cells, the triangular cobblestone morphology dominated,
while the pooled PAX6 control cells had similar morph-
ology to the WT and the 1.7 cells (Fig. 2b) The morph-
ology of the pooled Rescue cell lines are similar to pooled
PAX6 KO, but with more dominance of elongated cells
(Fig. 2b). The pooled cells were kept for five passages for
experiments, with the described variety in morphology
being constant during this time. We showed that knocking
out PAX6 alters the cell morphology, with the main fea-
ture being a reduction in the elongated neural morphology
of the U251 N WTcells.
Knock out of PAX6 increases colony formation and alter
colony morphology
To investigate the cells ability to maintain cell growth and
form colonies independent of contact with surrounding
cells, we performed colony formation assays. It has previ-
ously been shown that mir-335 affect the colony forming
abilities of glioma cells, and that regulation of PAX6
expression contribute to this [32]. We performed success-
ful colony forming assays for the KO 2.10 cells, the PAX6
control 1.7 cells and the WT cells. The variety of morph-
ology between the individual KO cell lines was reflected in
the various forms of colonies observed in the assay. We
observed three different types of colonies, tight,
a b
c d
Fig. 1 PAX6 is knocked out by CRISPR-Cas9 technology in U251 N glioblastoma cells and reintroduced by an EGFP-PAX6 expressing plasmid (a)
Western blot on cell lysates originating from single cell clones after CRISPR-Cas9 treatment. PAX6 Control cells have undergone CRISPR-Cas9
treatment and single cell sorting but still express PAX6. Detection by anti-PAX6 antibody. Actin staining was used for loading control. KO, knock
out; WT, wild type U251 N; L, Molecular weight marker. b Immunocytochemistry (ICC) on WT U251 N and pooled PAX6 KO cell lines (2A.3, 2A.28
and 2.10). Anti-PAX6 antibody detect endogenous PAX6 protein, DAPI staining identifies the nucleus. Scale bars indicate 10 μm. c Western blot
on the individual PAX6 KO cell lines transduced with a Dox inducible EGFP-PAX6 expressing plasmid (2A.3R, 2A.28R and 2.10R). The right panel
show cells treated with 10 ng/ml Dox for 24 h. Anti-PAX6 and anti-Actin antibodies were used for detection. d ICC of Dox treated pooled Rescue
cells expressing EGFP-PAX6. EGFP is detected as green fluorescence, anti-PAX6 antibody stain PAX6 protein, and the nucleus is stained by DAPI in
blue. Scale bar indicates 20 μm. Western blots and ICCs were performed on more than three samples of each cell line and showed the same results
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intermediate and loose, like described for U251 WT by
Cao and colleagues [31]. Sixteen days after seeding, the
WT cells had formed mainly large colonies. The colonies
were loose or intermediate with a center of tightly packed
cells. In addition, WT formed tight colonies after 12 days
and 16 days (Fig. 3a, b, e). The PAX6 control 1.7 cells
formed colonies similar to WT, while the PAX6 KO 2.10
cells formed mainly smaller tighter colonies, often with
cells on top of each other or tightly packed (Fig. 3a). The
PAX6 KO 2.10 cells covered a smaller surface area than
the colonies formed by the WT- and the PAX6 control 1.7
cells, but they seemed to contain the same number (or
even a higher number) of cells.
The three different PAX6 KO cells lines, and the four
different PAX6 control cell lines, were pooled and used
in colony-formation assays. The colonies formed by the
pooled KO cells displayed more variety than what was
observed for the 2.10 KO cells alone (Fig. 3b), probably
reflecting the differences in morphologies observed for
the individual KO cell lines (Fig. 3a). EGFP-PAX6
Rescue cells were also used in colony formation assays,
and the colonies formed were smaller compared to the
PAX6 KO cells, but had the same morphologies of tight,
intermediate and loose (Fig. 3c). The colonies formed by
PAX6 KO cells were denser and more tightly packed
than the colonies formed by the WT and the PAX6
control cells, and thus strongly stained by crystal violet
(Fig. 3d). Colonies were counted if they contained more
than fifty cells. However, due to the tight packing of the
colonies formed by the PAX6 KO cells, some colonies
having more than fifty cells may have been overlooked
during counting. As an illustration, arrows in Fig. 3d
indicate PAX6 KO colonies estimated to have more than
fifty cells, and WT colonies indicated to have less than
fifty cells. Initial experiments clearly showed that KO
cells had increased colony formation capabilities
compared to the wild type U251 N cell line. Further,
experiments with pooled Rescue cells indicated reduced
colony formation compared to pooled KO cells after
Dox stimulation, but the standard deviations were too
large to be considered statistical relevant (data not
shown). To clarify the colony forming ability of the indi-
vidual cell lines, the three KO cell lines (2.10 KO, 2A.3
KO and 2A.28 KO) and the Rescue cell lines derived
from these (2.10 R, 2A.3 R and 2A.28 R) were used in
colony formation assays together with WT U251 N cells.
For the Rescue cells, both Dox stimulated and unstimu-
lated cells were used. The Dox stimulated Rescue cells
were FACS sorted for EGFP-PAX6 expression 16–24 h
after stimulation and allowed to recover for 1 day before
they were seeded for this assay. The KO cell lines and the
U251 N cell line were also grown in media containing
Dox, so that potential differences observed are the result
of induced PAX6 expression and not the presence of Dox.
The experiment was done three times in triplicate, and a
representative result is shown in Fig. 3e. This shows that
the different KO clones have huge variations in their cap-
ability to form colonies, with the 2A.3 KO cell line being
equally bad as the U251 N cell line in colony formation
(less than 1% of seeded cells formed colonies), while the 2.
10 KO and 2A.28 KO cell lines were far better, with
efficiencies ranging from 7 to 22% for 2.10 KO and 32–
51%for the 2A.28 KO in three experiments (Table 4). The
ability of the Rescue cells to generate colonies were similar
to their original KO counterpart, but especially the 2A.3 R
cell line was better than its KO counterpart in colony
formation. However, Dox stimulation and FACS sorting of
EGFP-PAX6 expressing Rescue cells did not lead to
changes in the ability to form colonies in any of the three
Rescue cell lines (Fig. 3e).
a
b
Fig. 2 The PAX6 KO cell lines show morphological variations. Cells were micro-photographed at 20×. a KO cells and controls. b Pooled PAX6 KO-,
PAX6 Control, and PAX6 Rescue cells
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To summarize, we have shown that PAX6 influences
colony morphology, and that the ability to form colonies
is enhanced in two of three PAX6 KO cell lines compared
to the U251 N cells.
Migration pattern and speed is altered by PAX6 KO
The observed morphology of individual cells and cell
colonies could indicate differences in mobility between
the PAX6 KO cells and the PAX6 control (or WT) cells.
To test this, migration assays were performed on pooled
cells. The cells were treated with Mitomycin C to abolish
proliferation. At 20 and 48 h after removal of well
inserts, the PAX6 KO cells covered a larger area than
WT and PAX6 control cells did (Fig. 4a). After 72 h, the
entire region (originally cell-free at 0 h) was covered by
the PAX6 KO cells. The WT and the control cells did
not migrate at the same speed and there were still cell-
free areas at 72 h after removal of well inserts. The
differences in migration distance between the three cell




Fig. 3 Knock out of PAX6 alters morphology of colonies and increases colony-formation ability. Five hundred cells (WT, Control or KO) per well
in a 6-well plate was seeded and left for (a) 16 days or (b) 12 days to study colony forming abilities. c Five hundred cells of the Dox inducible EGFP-PAX6
pooled rescue cell lines and the pooled PAX6 KO cells were seeded per well in 6-well plates and left for 12 days. Colonies were micro-photographed.
d Colonies were stained with 0.005% crystal violet before counting. Arrows indicate WT U251 N colonies containing less than 50 cells, and PAX6 KO
colonies containing over 50 cells. e Five hundred cells were seeded in three wells in 6-well plates and left to form colonies for 12 days for each of the
PAX6 KO cell lines (2.10 KO, 2A.3 KO and 2A.28 KO), and their Rescued counterparts (2.10 R, 2A.3 R and 2A.28 R) as well as the WT cell line U251 N. Pooled
versions containing equal amounts of each of the three individual cell lines within each group were also included (3xKO, 3xR and 3xR +Dox). The term
“+DOX” indicate Rescue cells treated with Dox 18–24 h before FACS sorting. The day after FACS sorting they were seeded for the colony formation assay.
Rescue cells without Dox treatment were also included. Colony-forming abilities were measured by counting colonies consisting of over 50 cells. The
figure is representative of three experiments done in triplicate. For each experiment the colonies were counted by two persons.
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relevant and show that the PAX6 KO cells have increased
migration capacity compared to the PAX6 expressing cells;
even though the morphology of WTcells (elongated, form-
ing loose colonies) indicated that they would be more mo-
bile. The results are in line with what others have found
for PAX6 with regard to migration and invasion, e.g. in
murine astrocytes reported by Sakurai et al. [33], and in
glioblastoma cell lines, shown by Pavlakis et al. [34], Cheng
et al. [32] and Mayes et al. [20].
PAX6 KO cells have higher proliferation rate and altered cell
cycle distribution compared to WT and PAX6 control cells
In order to investigate the proliferation rate of the PAX6
KO cells compared to the WT cells, proliferation assays
were performed by seeding cells and counting them at dif-
ferent time points. Regulation of PAX6 expression levels by
miR-335 indicates that PAX6 restrict cell proliferation in
glioblastoma cell lines [32]. The PAX6 KO 2.10 cells clearly
proliferated faster than WT cells and the PAX6 control 1.7
cells (Fig. 5a). Pooled cells displayed the same pattern (Fig.
5b). The reintroduction of EGFP-PAX6 into the KO cells
(generating Rescue cells) caused a clear reduction in prolif-
eration when Dox stimulated and FACS sorted before use
(Fig. 5c). PAX6 has been shown to be involved in cell cycle
regulation in many cells and tissues, however it affects cell
cycle differently in various cell types [17, 35–37]. We there-
fore wanted to investigate if there were changes in cell-
cycle distribution in the PAX6 KO cells compared to the
PAX6 expressing cells. The results showed that by knock-
ing out PAX6 the percentage of cells in G0/G1 decreased
more than 50% (Fig. 5d and e). This indicates that PAX6
keeps cells in the G0/G1 phase of the cell cycle. PAX6 KO
cells showed a strong increase of cells in the G2/M phase
(50% increase compared to the WT and the PAX6 control
cells), with a strong reduction of cells in G0/G1- and S
phase. For the PAX6 Rescue cells, the number of cells in
the G0/G1 phase increased, while the number of cells in
the G2/M phase decreased (Fig. 5d and e), creating a slight
shift in the cell-cycle distribution for the PAX6 KO Rescue
cells towards the WT distribution. To investigate if pro-
longed incubation with Dox would result in increased
PAX6 expression (and thus less heterozygosity), the incu-
bation time and concentration with Dox was increased to
6 days and 25 or 50 ng/ml. However, the results main-
tained the same. The difference in number of cells in G1/
G0-phase for PAX6 KO cells compared to Rescue was
small but significant, with a p-value < 0.05. Use of Dox
Table 4 Percentage of colony formation ability in various PAX6
KO and Rescue cell lines
Cell lines Exp.1 Exp.2 Exp.3
U251 N 0.3 0.6 1.0
2.10 KO 7.3 22.6 9.3
2A.3 KO 0.1 0.2 0.0
2A.28 KO 45.2 32.0 50.9
3xKO 21.4 17.2 22.4
2.10 R 7.0 40.8 42.7
2A.3 R 1.0 11.9 16.2
2A.28 R 20.3 42.1 44.2
3xR 19.5 34.1 42.1
2.10 R + DOX 17.1 35.5 27.4
2A.3 R + DOX 1.1 1.9 14.7
2A.28 R + DOX 19.8 37.6 39.1
3xR + DOX 19.4 28.9 38.0
a b
Fig. 4 PAX6 KO cells migrate faster than WT and control cells. a WT U251 N cells, pooled PAX6 control cells and pooled PAX6 KO cells were seeded in
Ibdi 2-well silicone inserts and left for 24 h. Cells were Mitomycin C treated for 2 h before inserts were removed, creating a cell free area (gap) at the
start of the assay. Cells were micro-photographed at 0, 20, 48, and 72 h after well inserts were removed. The white lines demark migration edges. b
The average migration distance was calculated after 20 h as described in methods. Students t-test showed that the difference in migration distance
observed between pooled PAX6 KO cells and WT U251 N was significant (p < 0.002). The difference between pooled PAX6 Control cells and WT
U251 N cells was not. Migration assays were repeated three times. Each assay showed the same result
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stimulated and FACS sorted Rescue cells did not change
this result (results not shown). Cyclin D1 and p27 have
both been shown to be involved in PAX6 regulation of cell
cycle in other cell lines [37, 38]. We therefore compared
the expression of these genes in the PAX6 KO cells and
WT cells, by use of RT-qPCR. We observed minor fold
changes (− 1.5) between PAX6 KO and WT cells with re-
gard to p27 expression. However, for cyclin D1 there was a
fold change of − 2.4 in the PAX6 KO cells compared to the




Fig. 5 PAX6 restricts cell proliferation and regulates cell cycle. a Fifty thousand WT U251 N cells, PAX6 1.7 Control cells and PAX6 2.10 KO cells
were seeded at day 0 and counted at day 2, and 3. Proliferation assays were repeated three times. b Fifty thousand WT U251 N cells, pooled
PAX6 Control cells and pooled PAX6 KO cells were seeded at day 0 and counted at day 1, 2, and 3. c The Cell Titer Glo assay was used to
compare proliferation (viability) in the WT U251 N cell line with the Rescue cell line treated with and without Dox. Dox treated Rescue cells were
FACS sorted so that all cells expressed EGFP-PAX6. Values obtained at day 1 was set to 1, and the fold increase in proliferation at day 2 and 3 was
calculated. Three independent experiments show similar results. d The cell cycle distributions of WT U251 N cells, pooled PAX6 control cells and
pooled PAX6 KO cells at 70–90% confluency were examined by PI staining and FACS (upper panel). WT U251 N cells, pooled PAX6 KO cells and
pooled PAX6 Rescue cells were Dox treated, and the cell cycle distributions were investigated at 70–90% confluency by PI staining and FACS
(lower panel). e Average cell-cycle distribution from three experiments of cells mentioned in D. Student’s t-test, p < 0.05
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mediated by regulation of cyclin D1 expression, the
opposite would be expected, that is; lower level of cyclin
D1 in the WT cells that were arrested in the G1/G0 phase
of the cell cycle. An alternative explanation for the low
level of Cyclin D1 in the PAX6 KO cells is the fact that a
higher proportion of these cells are in the G2 phase of the
cell cycle, and thus would be expected to have lower level
of Cyclin D1 expression since the expression varies
through the cell cycle. Hence, by harvesting and comparing
mRNA from cell populations with striking differences in
their G1 to G2 phase distribution one would expect differ-
ences in the level of Cyclin D1 mRNA.
To summarize, PAX6 KO cells proliferate at a higher
rate, and display altered cell cycle distribution with accu-
mulation in the G2/M phase compared to the WT and
PAX6 control cells.
PAX6 KO cells display enhanced resistance to oxidative
stress
There are reports linking PAX6 to oxidative stress in
glioblastoma cells [23]. H2O2 is naturally produced in
large amounts by tumor cells [39–42]. To assess whether
PAX6 KO, WT and control cells were differently affected
by oxidative stress we exposed the PAX6 2.10 KO cells,
the WT and the PAX6 1.7 control cells to various con-
centrations of H2O2 for 24 h. At the H2O2 concentration
of 60 μM the PAX6 2.10 KO cells displayed minor
changes, with a small proportion of the cells rounded
up. However most of the cells still looked vital and
attached. Similareffect was obtained using a 3 times
lower concentration of H2O2 (20 μM) on the WT and
the PAX6 1.7 control cells. At 60 μM H2O2 most of the
WT and PAX6 1.7 control cells were rounded up or
detached from the surface (data not shown). This
confirmed that the presence of PAX6 renders the cells
more sensitive to oxidative stress.
To investigate this further, we incubated pooled PAX6
KO cells, WT, PAX6 control and PAX6 Rescue cells in
300 μM H2O2 for 24 h. The concentration of 300 μM
was chosen as Chang and colleges found that PAX6
increased glioma cell sensitivity to detachment induced
oxidative stress at ROS levels comparable with what
300 μM H2O2 induce [23]. Cells were stained with PI
and anti-Annexin V FITC, and analyzed by FACS. The
results strongly support that the PAX6 KO cells have a
higher tolerance to H2O2 induced oxidative stress than
WT cells (Fig. 6a and b). While 50% of the H2O2 treated
KO cells were healthy and intact, less than 20% of the
WT and PAX6 control cells were viable. The highest
percentage of late apoptotic and dead cells (79%) were
found in the sample of PAX6 control cells, closely
followed by the WT cells (72.9%). For PAX6 KO cells
only 41.5% were found to be late apoptotic or dead. In
line with this, the PAX6 Rescue cells displayed less
viable cells and increased the percentage of apoptotic
cells upon H2O2 treatment compared to the PAX6 KO
cells (Fig. 6a). This was observed for the cells even
without Dox treatment, and we believe that is due to the
leakiness of the Dox inducible system. However, the
difference was more pronounced for Dox induced cells
(Fig. 6b). While Dox in combination with H2O2 had no
effect on the amount of live PAX6 KO cells (52.7% vs
50.1% in Dox stimulated vs unstimulated cells), the com-
bination of Dox and H2O2 caused even more reduction
in live Rescue cells (26.6% vs 31.1% in Dox stimulated vs
unstimulated cells) (compare respective panels in Fig. 6a
and b). This indicates that the increased PAX6 expres-
sion in the cells make them more sensitive to H2O2. To
summarize, these results show that depletion of PAX6
affects cell morphology, cell proliferation, cell cycle dis-
tribution and sensitivity to oxidative stress – and these
changes are reversed by re-introduction of PAX6 using a
Dox inducible PAX6 expression vector. Furthermore,
PAX6 depletion also highly enhanced the formation of
colonies in a colony formation assay. However, this was
not reversed by reintroduction of PAX6.
TMZ is more lethal to PAX6 KO cells compared to WT and
control cells, while the opposite is observed for
Withafarin a
To investigate if PAX6 and its ability to render cells
more sensitive to oxidative stress would play a role in
treatment of glioblastoma, we treated the PAX6 KO cells
and controls with various chemotherapeutic agents;
Temozolomide (TMZ), Withaferin A (WA) and
Sulforaphane (SFN). TMZ treatment, 250 μM for 72 h,
reduced the cell number of both the WT and the PAX6
KO cells compared to untreated cells as observed in the
microscopy. FACS was used to investigate the propor-
tion of live and dead cells. As shown in Fig. 7, the TMZ
treated PAX6 KO cells had more than double the
amount of cells in the category late apoptotic/necrotic/
dead cells compared to the WT cells. This clearly shows
that PAX6 expression is beneficial for cell survival after
TMZ treatment. WA treatment, 1.5 μM for 48 h,
showed no differences in the percentage of cells in late
apoptosis/necrosis for the WT (49%) and KO (48.4%).
However, there were less live cells, and more early apop-
totic cells for the WT (40.2 and 10.8% respectively) than
for the PAX6 KO cells, where the comparable numbers
for live and early apoptotic cells were 47.9 and 3.7%,
respectively (Fig. 7). WA induces oxidative stress in
cancer cells [43] and that may be the reason for WT
cells being more sensitive to the treatment compared to
PAX6 KO cells. Treatment with SFN, 10 μM for 48 h,
seemed to strongly reduced proliferation in both PAX6
KO and control cells when observed in the microscopy.
PAX6 KO cells displayed a slightly higher percentage of
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vital cells (84.3%) compared to the WT cells (76.4%),
which had more apoptotic cells in the FACS analyses
(Fig. 7). This strongly support that PAX6 expression
sensitizes U251 N cells to chemotherapy treatment.
PAX6 KO and WT cells show differences in gene
expression for MMP2, CAV1, cyclin D1 and Nrf2
Changes in gene expression between PAX6 KO cells and
WT cells were studied by RT-qPCRs for selected genes
(MMP2, CAV1, Cyclin D1, p27, and Nrf2) (Table 4)
known to be regulated by PAX6, or known to participate
in proliferation, migration and/or redox regulation.
MMP2 is involved in migration and is a known PAX6
target [20]. To our surprise, the PAX6 KO cells showed
a 5-fold reduction of MMP2 compared to WT cells
(Table 5). This is contradictory to what others have
shown [20]. Another gene involved in migration and
proliferation is CAV1. RT-qPCR showed a 2-fold down-
regulation of CAV1 in the PAX6 KO cells, which is in
line with what we have observed when PAX6 was
knocked down in the pancreatic adenocarcinoma cell
line HPAFII (Forsdahl et al: in preparation). In the
Fig. 6 PAX6 KO cells are less sensitive to oxidative stress. Cells were exposed to 300 μM H2O2 for 24 h, and Annexin V FITC /PI stained before
FACS analysis. Percentage of viable cells, cells in early apoptosis and cells in late apoptosis/necrosis were determined. a Cells without Doxycycline
treatment. b Doxycycline treated cells. Figure shows representative results from three to four experiments
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HPAFII cell line, knockdown of PAX6 caused enhanced
proliferation and migration, in addition to the reduced
expression of CAV1 (results not shown). Cyclin D1 and
p27 are known target genes of PAX6 [44, 45], and im-
portant molecules regarding the regulation of cell cycle
progression. PAX6 KO cells had a 2.4 fold downregula-
tion of cyclin D1 compared to WT, while p27 expression
was not significantly affected by PAX6 KO (Table 5).
High levels of Cyclin D1 is required for the progression
from G1 to S in the cell cycle. The expression of cyclin
D1 is expected to be low or absent in most of the other
cell cycle phases, although cancer cells may show aber-
rant regulation. A reduction in PAX6 KO cells in the
G0/G1 phase compared to WT cells (as shown in Fig.
5D), might reflect the difference in cell cycle distribution
between the PAX6 KO and WT cells, and not the PAX6
regulation of Cyclin D1 expression. Nfr2 is a key regula-
tor of the oxidative stress defense mechanisms, and con-
trols the basal and the induced expression of an array of
antioxidant response element–dependent genes [46].
PAX6 KO cells has a 3.7 fold downregulation of Nrf2
compared to WT cells (Table 5), which is interesting
since we have shown that these cells are in fact more re-
sistant to oxidative stress by H2O2. PAX6 expressing
cells are thus more sensitive to oxidative stress despite
having higher expression of Nrf2 than the PAX6 KO
cells. This urge that the effect of PAX6 on other regula-
tors of oxidative stress responses should be included in
further studies.
Discussion
PAX6 is frequently expressed in tumors [13–16]. In
glioblastoma, PAX6 expression is associated with glioma
grade. From the development of anaplastic astrocytoma
into stage IV glioblastoma the expression level of PAX6
decreases by 3 fold, and GBM tumors have 2–12 fold
less PAX6 expression compared to surrounding normal
tissue [18].
In our studies, we have as the first created a tool by
successfully knocking out PAX6 in the U251 N glioblast-
oma cell line using the CRISPR-Cas9 technology. We
have demonstrated that complete absence of PAX6 by
Fig. 7 PAX6 KO cells respond differently to treatment with the chemotherapeutic drugs TMZ, WA and SFA compared to WT cells. U251 N
PAX6 KO and WT cells were treated with 250 μM Temozolomide (TMZ), 1.5 μM Withaferin A (WA) and 10 μM Sulforophane (SFA) for 48
(WA and SFA) or 72 (TMZ) hours and analyzed for apoptosis by anti-Annexin/PI staining and FACS. The experiment shown is representa-
tive of three independent experiments
Table 5 RT qPCR shows negative fold change of gene expression in PAX6 KO cells compared to WT. ΔΔCt method was used for
analysis
Gene abbreviation Protein name Fold change # ± SD
MMP2 Matrix metalloproteinase 2 −5.0 ± 1.50
CAV-1 Caveolin-1 −2.0 ± 0.24
CCND1/ cyclin D1 Cyclin D1 −2.4 ± 0.14
CDKN1B/ p27 Cyclin-dependent kinase inhibitor 1B (p27Kip1) −1.5
NFE2L2 / Nrf2 Nuclear factor (erythroid-derived2)-like 2
NFE2L2 or Nrf2
−3.7 ± 0.68
The relative amount of target gene normalized to the average expression of the two reference genes TFRC and GAPDH was determined using the ΔΔCt-method
[71]. WT values were put as 1, and fold change according to this were calculated for the other cell types/treatments
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KO causes increased proliferation, migration and colony
forming abilities, confirming that PAX6 acts as a tumor
suppressor in glioblastoma cells lines. We also observed
that one of the three morphology types normally present
in U251 N cells dominates in the KO cells. The U251 N
cells neuron-like elongated morphology was reduced.
This was interesting, as PAX6 has been demonstrated to
alter cell morphology of HeLa cells when introduced by
transfection of a lentiviral vector. The HeLa cells formed
neurite-like extensions, and neuron-specific genes were
upregulated [47]. The dominant morphology of the col-
onies derived from single PAX6 KO cells was also differ-
ent from the one observed with WT cells. Furthermore,
a shift in cell cycle distribution was apparent in the KO
cells where the majority of the cells was in G2/M-
phase, while for WT cells the majority was in G0/G1.
This suggests that PAX6 is involved in keeping the cells
in the G0/G1 phase of the cell cycle. Rescuing the KO
cells through viral transduction of an EGFP-PAX6
expressing vector, led to a slight reduction of cells in
the G2/M-phase with a corresponding increase in num-
ber of cells in G0/G1. We also found that PAX6 KO
cells are more resilient than WT cells to oxidative stress
caused by exposure to H2O2. The rescue cells contain-
ing EGFP-PAX6 clearly made the cells more sensitive
to oxidative stress.
We found a variety of CRISPR-Cas9 generated mutations
in the PAX6 gene when genomic DNA from the knock out
cell lines were cloned and sequenced (Additional file 2:
Figure S2). Although U251 cells and other cancer cells have
ongoing chromosomal- and chromosome structure
instabilities [48] including variation in chromosome
number [25], it is unclear whether chromosome 11, where
PAX6 is located, is amplified [48, 49]. Regardless of this, the
fact that we observe three to seven different mutated
sequences for all our single cell clones either imply that
they were not single cells upon sorting, or that one or both
of the PAX6 alleles in the single cell were not mutated by
CRISPR-Cas9 at the time of sorting, even though the cells
expressed the vector marker EGFP. Mutations generated by
the CRISPR-Cas9 construct after the first and second cell-
division would then contribute to the observed variation in
mutation sequences. Importantly, complete absence of
PAX6 protein was confirmed by western blot and immuno-
cytochemistry for all the generated PAX6 KO cells.
The generated PAX6-EGFP inducible rescue cells were
able to rescue the observed effect of the PAX6 KO on pro-
liferation and oxidative stress, but they were not able to
shift the cell cycle distribution back to the one observed
for the WT cells, nor were they able to reduce the colony
forming abilities or the changes in gene expression for the
selected genes. Since PAX6 is known to function in a dose
dependent manner [50, 51] we initially thought that the
partial and heterogenous expression of PAX6 upon Dox
exposure (revealed by the ICC) was the main reason for
this. Not all Rescue cells expressed EGFP-PAX6, and the
ones that did, did it at different concentrations. The selec-
tion of EGFP-PAX6 expressing cells by FACS ensured that
all cells in the experiment expressed PAX6, but the level
of PAX6 expression in each cell was still variabel. The
dependency on correct dose of PAX6 might vary from one
biological process to another, and might explain why we
observed a rescue with regard to e.g. proliferation and not
colony formation. In addition, the time the cells were
exposed to the PAX6 protein before the colony formation
assay, cell cycle distribution experiments or gene expres-
sion studies were started, might play a role, depending on
the target genes and pathways affected by PAX6. In
theory, removal of PAX6 in the PAX6 KO cells may have
started a change in the cells that are “locked”, and not
reversed by just adding PAX6 back again (e.g chromatin
modifications making PAX6 target genes inaccessible).
Finally, the rescue construct provided the main isoform
PAX6, and not the PAX6(5a) isoform, which is shown to
play a part in eye, pancreas, neural development, pancre-
atic cancer and glioblastoma development [34, 52, 53].
Recently, PAX6(5a) was shown to play an important role
in regulation of glioma progression by reducing cell sur-
vival and decreasing migration and invasion in glioblast-
oma cell lines [34]. It did this by downregulating the lipid
kinase SPHK1, a gene previously identified by our
research group as a PAX6(5a) specific target gene [27].
U251 N WT cells have three different morphologies of
cells and colonies derived from single cells [31]. We
observed that removal of PAX6 made the small cobble-
stone morphology dominant. This morphology forms
tight colonies. However, the two other morphology types
were also observed, but to a lesser extent than what was
observed for WT cells. It has previously been shown that
PAX6 is involved in regulating cell morphology both in
cerebellar granule cells during neurogenesis and in
pancreas [52, 54, 55]. Yamasaki et al. [54] found that
PAX6 mutant (sey2/sey2) cerebellar granule cells are less
elongated than WT cells and have random migration
that may be due to aberrant cytoskeletal control. The
majority of the PAX6 KO cells in our experiments are
also less elongated. Interestingly, we observed that the
PAX6 KO cells migrate mainly as sheets, while WT and
PAX6 control have more elongated cells extending out
in the direction it is heading. This indicates that our
PAX6 KO cells have cytoskeletal changes that not only
affect the morphology, but also the pattern of migration.
The PAX6 KO cells migrated more efficiently than the
WT cells in scratch assays. Changes in speed of cell
migration by PAX6 KO or knockdown is also shown by
others [52, 56, 57]. Astrocytes from PAX6 mutant (sey/
sey) mice are shown to migrate faster than astrocytes
from WT mice in scratch assays [33]. It has also been
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shown that U251 cells that stably overexpress PAX6
show reduced migration and invasion capacity [20].
Several publications show, that PAX6 affects cell prolifer-
ation, but the effect is cell-, tissue- and context dependent
[17, 38, 52, 58]. We found that absence of PAX6 in the
U251 KO cells increased both the proliferation and the
ability to form colonies. This is in line with what others
have found. Colony formation is an in vitro cell survival
assay based on the ability of a single cell to grow into a col-
ony. The size of the colony is affected by the cells doubling
time. Proliferation and colony formation of glioblastoma
cells increased when miR-335 caused an approximately 2-
fold downregulation of PAX6 [32], and astrocytes from
PAX6 (sey/sey) mutant mice proliferate faster than the cor-
responding cells in the WT mice [33]. Others have shown
that over-expression of PAX6 in U251 cells reduced colony
formation ability in soft agar assays, but it did not affect cell
doubling time in U251 [17]. Complete absence of PAX6 in
our KO cells increased colony formation, and by that we
confirmed the role of PAX6 in reducing the glioblastoma
cell lines ability to form colonies from a single cell.
PAX6 is reported to influence the cell cycle distribution
in different cell types, however the mechanisms and direc-
tion of regulation are cell context- and tissue- dependent
[17, 35, 38, 58]. In our study, we retrieved clear results
showing that the percentage of PAX6 KO cells in the G0/
G1 phase of the cell cycle decreased, while the percentage
found in the G2/M phase increased compared to WT
cells. This is in line with what others have observed for
glioblastoma cells [17] and corneal epithelial cells [58].
We found that reintroducing PAX6-EGFP to our KO cells
increased G1/G0 and lowered G2/M-phase. However, the
percentage of PAX6 rescue cells in the G0/G1 phase did
not reach the same level as for WT. With the possible
dose-dependency of PAX6 in mind, we increased Dox
concentration to elevate PAX6 expression. The cells were
incubated in Dox for up to 5 days, but cell cycle distribu-
tion remained the same as for 24 h Dox stimulation (data
not shown). FACS sorting of cells after Dox induction
gave the same result. In glioblastoma cell lines and in
corneal epithelial cells, PAX6 overexpression retains cells
in G0/G1, retarding the passage of cells through the cell
cycle [17, 58]. The study of the corneal epithelial cells was
conducted using a Dox-inducible system in WT cells, as
we did in our rescue cells. While our rescue cells were a
heterozygous mix of different expression levels. Their
inducible cells were selected for high homozygous expres-
sion of PAX6 after 24 h of Dox induction, which was the
time frame of Dox-induction during their experiments. By
use of adenoviral transductions of U251 to overexpress
PAX6, or the use of a dominant negative PAX6, Zhou and
colleagues [17], concluded that PAX6 suppresses cell
growth by inhibition of the G1/S transition. Interestingly,
although PAX6 was shown to inhibit cell proliferation also
in HeLa cells, the accumulation of cells was in the G2/M
phase [59]. Our studies support that PAX6 has a role in
G1/S cell cycle arrest, since we see a shift in the cell cycle
distribution from G0/G1 in WT cells to G2/M in PAX6
KO cells. Although it seems that most studies support an
inhibitory role for PAX6 with regard to cell cycle regula-
tion, it is reported that in in lung cancer PAX6 promote
cell cycle transition from G1 to S phase [38].
PAX6 has been shown to exert its effects on cell cycle
progression by various mechanisms. In HeLa cells PAX6
has an antiproliferative effect by increasing expression of
human RFPL1 (Ret finger protein-like 1) that controls
cell cycle progression through cyclin B1/Cdc2 degrad-
ation. This delays mitosis entry and causes accumulation
of cells in G2/M-phase [59]. In lung cancer PAX6
knockdown cell lines, cyclin D1 is suppressed, indicating
that PAX6 promote cell cycle transition from G1 to S-
phase [38]. In addition, the pRB (Retinoblastoma) S780
phosphorylation level is decreased in lung cancer PAX6
KD cells. Cyclin D complexes phosphorylate the pRB
family of nuclear phosphoproteins to regulate the G1/S
transition [60]. The PAX6 regulation of cell cycle in lung
cancer cells was through the MAPK signal pathway as
they found that reduction of PAX6 decreased ERK1/2
and p38 phosphorylation [38].
Cancer cells produce high levels of reactive oxygen
species (ROS), and are under intrinsic oxidative stress
[39]. In the increased necrotic areas that are one of
the characteristics of GBM, the level of ROS is
elevated [3]. Cells must be resilient to the oxidative
stress to maintain viability. Interestingly, we found
that the PAX6 KO cells were substantially more resist-
ant to oxidative stress generated by addition of H2O2,
compared to PAX6 WT cells. When incubated in
300 μM H2O2 for 24 h we observed that 48% of PAX6
KO cells versus 74% PAX6 WT cells were in late apop-
tosis. We also found that KO cells had the morphology
of healthy and viable cells at H2O2 concentrations that
induced WT cells to round up, detach and enter apop-
tosis. PAX6 Rescue cells were more sensitive to oxida-
tive stress than the PAX6 KO cells. Chang et al. [23]
found that detachment of U251 cells by trypsin or
scraping increased ROS levels, and that this made
U251 cells that over-expressed PAX6 more susceptible
to detachment-induced stress compared to WT U251.
One knows very little about the mechanisms that
render PAX6 positive cells more sensitive to increased
ROS levels, but our results confirm the finding of
Chang and colleagues and show that several sources of
ROS have the same effect on glioma cells expressing
PAX6 [23].
Temozolomide (TMZ) is an alkylating agent which
delivers a methyl group to purine bases in DNA [61]. TMZ
is used as standard treatment for high-grade gliomas [61].
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GBM cells acquire chemo resistance to this drug as well as
to ionizing radiation and other chemotherapeutic agents
that elevate intracellular ROS [31]. TMZ causes increased
PAX6 expression in glioblastoma cell lines U251 and U118,
and TMZ is reported to depend on PAX6 expression to
decrease proliferation of GBM cells [24]. The oxidative
cytotoxic agent Withaferin A (WA) is a candidate for GBM
treatment. It re-sensitizes TMZ-resistant gliomas [62].
Grogan and colleagues found that this re-sensitization
works through depletion of O6-methylguanine-DNA
methyltransferase (MGMT) and the induction of apoptosis
through the AKT/mTOR pathway [62]. Knowing that WA
increases oxidative stress [62] and that TMZ increases
PAX6 expression (which sensitizes cells to oxidative stress),
can possibly provide an explanation of the molecular mech-
anisms behind the combined effect of WA and TMZ. In
TMZ treated cells, we did not observe any substantial
differences in proliferation inhibition between the WT and
PAX6 KO cells by simple microphotography, though the
PAX6 KO cells proliferated faster than WT as in untreated
cells. However, in FACS analyses we observed a doubling in
percentage of cell death induced by TMZ in PAX6 KO cells
compared to WT cells (41.3% vs 21.4%). Hence, it is clear
that knocking out PAX6 renders the cells more sensitive to
apoptosis from TMZ treatment. The opposite was observed
with WA, as this drug reduced viability in the WTcells to a
greater extent then what was observed for PAX6 KO cells.
The increased effectiveness of WA treatment in WT cells is
likely because of the drugs ability to induce oxidative stress,
which PAX6 expressing cells are more sensitive to. Sulfo-
raphane (SFN) was efficient in reducing proliferation in
both PAX6 KO and WT cells, however PAX6 KO cells had
a higher percentage of viable cells compared to WT in
FACS assays. SFN is known to induce growth inhibition
and apoptosis in human GBM cell lines GBM 8401 and
U251 [63, 64], and our results indicate that removal of
PAX6 makes the cells less sensitive to this drug. SFN can
similar to WA, reverse TMZ-resistance in glioblastoma
cells. SFN downregulates MGMT expression by inhibiting
the NF-κB pathway [65].
RT-qPCRs were performed to study the effect of PAX6
on various genes in U251 N. PAX6 KO cells had a reduc-
tion of MMP2 at − 5 fold compared to WT. MMP2 is
involved in migration and is a known PAX6 target, and
others have found PAX6 to suppress MMP2 expression
[20]. This is the contrary to what we show in our KO cells;
however, Mayes and colleges studied cells overexpressing
PAX6, and they used a different U251 cell line. CAV1 is
another gene involved in migration and proliferation. We
have identified CAV1 as a positively regulated target gene
of PAX6 in human pancreatic adenocarcinoma cell line
HPAFII (Forsdahl et al: in preparation). CAV1 is known to
reduce proliferation and clonogenicity of U87MG GBM
cells, and downregulation of CAV1 increase the cells
proliferation ability and invasiveness [66]. We found that
CAV1 is 2-fold downregulated in the PAX6 KO cells com-
pared to WT, which fit with observations in other glio-
blastoma cell lines where lower expression of CAV1
equals increased proliferation. Since cell cycle distribution
was altered in the PAX6 KO cells, RT-qPCRs on cyclin D1
and p27 were performed. PAX6 regulates Cyclin D1 in
lens cells and p27 in neuroepithelial (NE) progenitor cells
in the mouse optic vesicle [44, 45]. We did not find signifi-
cant changes in p27 expression when PAX6 was absent.
However, the PAX6 KO cells had a 2.4 fold downregula-
tion of cyclin D1 compared to WT cells. Cyclin D1 is im-
portant for progression through the G1/S checkpoint [67],
and is normally high in G1/M phase, reduced in S-phase
and then elevated again in G2 phase to promote prolifera-
tion [68, 69]. In addition, shRNA knockdown of Cyclin D1
has previously been shown to induce apoptosis and inhibit
proliferation of U251 cells [70]. However, since we observe
increased proliferation in the PAX6 KO cells despite the
downregulation of Cyclin D1, there must be other factors
responsible for the increased progression through cell
cycle and increased proliferation in the PAX6 KO cells
compared to WT. We observed that PAX6 KO renders
U251 N cells less sensitive to oxidative stress. The TF nu-
clear factor erythroid 2 (NFE2)-related factor 2 (Nrf2) is a
key regulator of genes involved in oxidative stress defense
[46]. We found the Nrf2 expression to be regulated by
PAX6 in glioblastoma cells, although it cannot be respon-
sible for the increased resistance for oxidative stress ob-
served in our PAX6 KO cells, since it is downregulated by
3.7 fold in this cell line. The RT-qPCR results differing
from theories based on what others have found shows the
complexity of the processes involved in increased tumori-
genecity in the PAX6 KO cells and in glioblastomas in
general.
Conclusion
With our novel tool and new approach to study the role
of PAX6 in glioblastoma, we have established that
PAX6 influence the cell cycle distribution, and renders
U251 cells more sensitive to oxidative stress. Import-
antly, we discovered differences in the sensitivity to
established chemotherapeutic drugs between the PAX6
expressing (WT) cells and the PAX6 KO cells. The
PAX6 KO cells are less sensitive to oxidative stress, and
to the drugs WA and SFN, compared to WT cells.
However, for TMZ treatment PAX6 KO cells show
more sensitivity and cell death than WT cells. Since the
level of the PAX6 protein expression changes with the
grade of glioblastoma, the observed variation in drug
responses can be valuable information when planning
treatment and developing new chemotherapies for
GBM patients. It will therefore be interesting to further
study the mechanisms behind the variation in cell
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responses to WA and TMZ treatment for the PAX6 KO
cells and WT cells.
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